Next-Generation Histone Deacetylase Inhibitors header


Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested in pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Cambridge Healthtech Institute’s eighth annual event on Next-Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family. The interactive sessions and panel discussions are all geared to provide ample opportunity for active networking, brainstorming and collaborating.

Topics will include, but are not limited to: 

  • New HDAC chemistries
  • Exploring HDAC biology
  • Using structural biology to guide chemical design
  • Screening HDAC inhibitors: Use of animal models and in vitro assays
  • Evaluating the use of pan versus isoform-specific inhibitors
  • Update on novel HDACi and their progress towards the clinic

Who should attend: Students, Post-docs, Lab Technicians, Managers, Scientists, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery of epigenetic targets, Functional Screening, Compound Screening, Target ID and validation, Biomarker Discovery, Translational Research, and Clinicians working on epigenetic drug targets.

If you are interested in speaking, please click here to submit a proposal.

The deadline for submission is April 4, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For questions or suggestions about the meeting, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 973-525-4667
E: tkoppal@healthtech.com 

For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Jon Stroup
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT CAG ICON 

green arrow CONFERENCE-AT-A-GLANCE 

PREMIER SPONSORS 

Cellecta 

green arrow VIEW ALL SPONSORS 

green arrow VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2013, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2014, contact:

Jon Stroup
Business Development Manager
781-972-5483
jstroup@healthtech.com